Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pafolacianine - On Target Laboratories

Drug Profile

Pafolacianine - On Target Laboratories

Alternative Names: CYTALUX; Folate fluorescein isothiocyanate conjugate - On Target Laboratories; Folate receptor-alpha-targeted fluorescent agent - On Target Laboratories; Folate receptor-alpha-targeted imaging agent - On Target Laboratories; OTL-0038; OTL-38; pteroyl-L-tyrosine-S0456

Latest Information Update: 14 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte; Purdue University
  • Developer Centre for Human Drug Research; Indiana University School of Medicine; Leiden University Medical Center; On Target Laboratories; Purdue University; University of Pennsylvania
  • Class Cyclohexenes; Fluoresceins; Haptens; Imaging agents; Indoles; Pteridines
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Registered Non-small cell lung cancer; Ovarian cancer
  • Phase II Endometrial cancer; Endometriosis; Renal cell carcinoma
  • No development reported Pituitary cancer; Primary hyperparathyroidism; Triple negative breast cancer

Most Recent Events

  • 06 May 2023 On Target Laboratories, GlaxoSmithKline and VU University Medical Center plan the phase I STRATIFY trial for Rheumatoid arthritis and Inflammatory bowel disease (Treatment experienced, Diagnosis) in Netherlands (IV), in June 2023 (NCT03938701)
  • 27 Mar 2023 Efficacy and adverse events data from the phase III ELUCIDATE trial in Non-small cell lung cancer (Diagnosis) released by On Target Laboratories
  • 31 Dec 2022 The US FDA approves a supplemental New Drug Application for Lung cancer in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top